Principal Investigator
Chukwuemeka Ikpeazu
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20210067
National Clinical Trials Identifier
NCT04675333
Clinical Trial Summary
A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in
Patients With Advanced Head and Neck Squamous Cell Carcinoma.
Phase
Phase 2
Funding Agency/Sponsor
Industrial
Disease
Head and Neck Cancer
Enrollment Eligibility
Inclusion Criteria:
- Previously untreated metastatic or unresectable, recurrent head and neck squamous cell
carcinoma.
- Adequate bone marrow function.
- Adequate renal and liver function.
- Adequate ECOG performance status.
Exclusion Criteria:
- Patients with known symptomatic CNS metastases or leptomeningeal disease requiring
steroids.
- History of (non-infectious) pneumonitis that required steroids or current pneumonitis.
- Prior treatment with any anti-CD47 or anti-SIRPĪ± agent.
- Prior treatment with anti-PD-1 or PD-L1.